Abstract Body

Background: Few studies have compared rates of hepatic decompensation in HIV/HBV/HCV and HIV/HCV patients. It is also unclear if anti-HBV nucleos(t) ide analogue therapy is effective at reducing decompensation rates in triply infected patients. Our objectives were to: 1) compare the incidence rates of hepatic decompensation in HIV/HBV/HCV and HIV/HCV patients, and 2) determine the risk of decompensation associated with anti-HBV nucleos(t)ide analogue-untreated and treated HIV/HBV/HCV. Methodology: We conducted a cohort study among HIV/HBV/HCV and HIV/HCV patients in the US Veterans Health Administration (VHA) between October 2005 and February 2012. All patients had HIV, detectable HCV RNA, and 12 months in the VHA. Chronic HBV was defined by 2 positive HBV surface antigen results and/or chronic HBV diagnoses recorded >6 months apart. Use of an anti-HBV nucleos(t)ide analogue was determined. The main outcome was incident hepatic decompensation (defined by one hospital diagnosis or two or more outpatient diagnoses for ascites, spontaneous bacterial peritonitis, or variceal hemorrhage). Follow-up began after 12 months in the VHA. Rates of decompensation were compared between HIV/HBV/HCV and HIV/HCV patients. Cox regression was used to evaluate adjusted hazard ratios (aHRs) of decompensation between triply and dual infected patients and to determine the risk of decompensation in anti-HBV nucleos(t)ide analogue-untreated and treated HIV/HBV/HCV patients compared to HIV/HCV patients. Results: Among 149 HIV/HBV/HCV and 4,902 HIV/HCV patients, the incidence rate and risk of decompensation was higher in triply than dual infected patients (24.1 versus 10.8 events/1,000 person-years; aHR=2.40 [95% CI, 1.44-3.99]). The risk of decompensation was substantially increased for HIV/ HBV/HCV patients with no anti-HBV nucleos(t)ide analogue use (aHR, 2.48; 95% CI, 1.37-4.49) but not for HIV/HBV/HCV patients receiving an anti-HBV nucleos(t)ide analogue (aHR, 1.09; 95% CI, 0.40-2.97) compared to HIV/HCV patients. Conclusions: HIV/HBV/HCV patients had higher rates of hepatic decompensation compared to HIV/HCV patients. The risk of decompensation was increased among triply infected patients who did not receive an anti-HBV nucleos(t)ide analogue. Controlling HBV viremia with HBV therapy is important to reduce rates of hepatic decompensation in HIV/HBV/HCV triply infected persons.